Related Experiment Video
Updated: Jun 14, 2026
07:34
Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
Published on: December 16, 2021
T-cell-directed therapies in inflammatory bowel diseases
Giovanni Monteleone1, Flavio Caprioli
1Department of Internal Medicine, University Tor Vergata of Rome, Rome, Italy. Gi.Monteleone@Med.uniroma2.it
Clinical Science (London, England : 1979)
|March 31, 2010
Summary
Inflammatory bowel diseases (IBD) involve uncontrolled T-cell immune responses in the gut. Therapies targeting T-cells effectively reduce gut inflammation and immune responses in IBD patients.
Area of Science:
- Immunology
- Gastroenterology
- Cell Biology
Background:
- Gut inflammation in inflammatory bowel diseases (IBD) is characterized by aberrant T-cell responses against gut microbiota.
- T-cells accumulate in the inflamed gut via increased recruitment, proliferation, and resistance to apoptosis.
- Activated T-cells release cytokines that exacerbate mucosal inflammation.
Purpose of the Study:
- To review the role of T-cells in IBD pathogenesis.
- To evaluate the efficacy of T-cell-directed therapies for IBD.
Main Methods:
- Review of existing literature on T-cell function in IBD.
- Analysis of clinical outcomes from T-cell-targeted treatments.
Main Results:
- T-cell accumulation and activation are key drivers of gut inflammation in IBD.
- Targeting T-cell accumulation and function has shown clinical success.
- T-cell-directed therapies mitigate tissue-damaging immune responses.
Conclusions:
- T-cell-mediated immunity plays a critical role in IBD.
- Therapeutic strategies focused on T-cells are beneficial for managing IBD.
- Modulating T-cell responses offers a promising approach for IBD treatment.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.